According to New Data Released at TCT 2016
Data Supports Potential Need for TriGuard™ Cerebral Embolic Protection device being developed by Keystone Heart
New data presented at PCR London Valves conference
Supporting data to be presented at Transcatheter Valve Therapies (TVT) Conference
Cardiovascular Device Industry Veteran Chris Richardson to Help Lead Company To Commercialization
Benefits of Keystone Heart’s TriGuard neuroprotection during TAVR in reducing stroke, CNS infarction and infarction size are supported by results from pooled analysis presented at EuroPCR 2016
Yale Led Study’s Findings Consistent with Multiple European Trials – Post Procedure MRI Reveals New Brain Lesions in 94% of TAVR Patients
Keystone Heart today announced that its CE marked TriGuard™ Cerebral Protection Device has improved in-hospital safety outcomes and cognitive scores at discharge during Transcatheter Aortic Valve Replacement (TAVR). Based on changes in NIH Stroke Scale, patients protected with TriGuard had 10% absolute reduction in stroke (4.9% vs. 14.3%). Minor strokes were under detected without detailed NIHSS assessment.
Resources will be channeled towards randomized clinical studies and further commercialization.
Keystone Heart will exhibit and present at EuroPCR next week in Paris.
CE Marking for the TriGuard™ device, devised to minimize the risk of brain damage during TAVR, enables commencement of commercial use
Recent data demonstrates considerable reduction of new brain lesion volume during protected TAVR procedures performed with the TriGuard medical device